Core Viewpoint - The recent ratings from seven authoritative institutions highlight that GF Fund has achieved significant recognition, with 103 of its products receiving five-star ratings, showcasing its strong research capabilities and diverse product offerings [1][2]. Group 1: Active Equity Products - Nearly half of GF Fund's five-star rated funds are active equity products, characterized by diverse styles and features [2]. - Notable products include GF Value Core A, which has effectively captured trends in new consumption and internet technology, earning five-star ratings from multiple institutions [2]. - GF Fund has standout products in various sectors, such as GF North Exchange Selected Fund, which received a three-year five-star rating from several institutions [2]. Group 2: Fixed Income Products - GF Fund has over 30 fixed income funds rated five stars, covering a range of types including money market, short-term pure debt, and mixed debt funds, catering to investors' demand for stable returns [2]. Group 3: Passive Index Funds - GF Fund offers a variety of investment tools, with 24 passive index funds and 4 passive bond index funds achieving five-star ratings [3]. - The GF CSI All-Share Medical and Health ETF has received five-star ratings across three, five, and ten-year periods from two institutions [3]. Group 4: Overseas and Multi-Asset Investment - GF Fund's active and passive QDII products are recognized as representative five-star funds in overseas investments [3]. - The GF Stable Pension (FOF) A has been awarded a five-year five-star rating, reflecting its multi-asset allocation strategy [3]. Group 5: Product Management and Quality Improvement - GF Fund has integrated customer profit experience into its product creation and management processes, aiming to enhance product quality and transition from a "product manager" to a "value creator" [3].

Group 1 - The core viewpoint of the article highlights that funds focused on innovative pharmaceuticals have seen significant gains, with some funds increasing over 61% in the first half of the year [1] - The top-performing funds include several that are primarily invested in innovative drugs, with the highest return being 86.48% for the fund "汇添富音港优势精选A" [1] - Other notable funds in the top 16 also show strong performance, with returns ranging from 61.77% to 83.15% [1] Group 2 - The article suggests that innovative drugs can be pursued when the market declines, indicating a potential buying opportunity [2] - The "广发成长领航一年持有A" fund has a significant portion of its holdings in new consumer concepts, with major investments in companies like 泡泡玛特 and 老铺黄金 [3] - The fund manager 吴远怡 has demonstrated strong performance across various products, with most showing commendable returns [4] Group 3 - The historical performance of the "广发科技创新" fund shows a maximum drawdown of -53%, indicating high volatility [5] - Overall, the funds discussed are characterized by high volatility and significant drawdowns, making them more suitable for investors willing to buy during market dips [7] - The article emphasizes that these funds may not be suitable for low-risk investors due to their performance characteristics [7]